Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jiangsu Recbio Technology Co., Ltd. has successfully completed the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40, is being tested for its efficacy and safety at multiple centers in China. With the market currently dominated by GlaxoSmithKline’s Shingrix, there is significant demand for a domestic alternative like REC610.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.